|
WEDNESDAY, DECEMBER 7, 2022 |
| |
|
|
| All times are CENTRAL Time
|
|
|
| 7:00 am - 8:15 am CT |
POSTER SESSION #2 - Hall 1
|
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #4 - Hemisfair Ballroom 1&2
Single Cell Approaches for Translational Research and Biomarker Discovery
Chair: Charles Perou, PhD
University of North Carolina
Chapel Hill, NC
Single Cell Genomics for Breast Cancer Outcomes
Christine Desmedt, PhD
Laboratory for Translation Breast Cancer Research/KU
Leuven, Belgium
Spatial Imaging and the Importance of Localization
Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia
|
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #5 - Stars at Night Ballroom 3&4
Advances in TNBC Biology
Chair: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX
Celina Kleer, MD, PhD
University of Michigan Medical School
Ann Arbor, MI
Brian Lehmann, PhD
Vanderbilt University Medical Center
Nashville, TN
|
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #6 - Stars at Night Ballroom 1&2
Special Populations: Male Breast Cancer/Geriatrics
Chair: Anne Blaes, MD, MSc
University of Minnesota
Minneapolis, MN
Geriatric Breast Cancer
Rachel A. Freedman, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Male Breast Cancer
Jose P. Leone, MD
Dana-Farber Cancer Institute
Boston, MA
|
|
| 8:20 am - 8:30 am CT |
Opening Ceremony/Welcome Message - Hall 3
Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX |
|
| 8:30 am - 9:00 am CT |
William L. McGuire Memorial Lecture - Hall 3
Moderator: Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Leveraging Preclinical Models for Translational Breast Cancer Research
Jeffrey Rosen, PhD
Baylor College of Medicine
Houston, TX |
|
| 9:00 am - 9:45 am CT |
GENERAL SESSION #2 - Hall 3
Moderators:
Hannah Linden, MD
University of Washington
Fred Hutchison Cancer Center
Seattle, WA
and
David Rimm, MD, PhD
Yale University
New Haven, CT
|
|
| 9:00 am - 9:15 am CT |
GS2-01: Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02
Krop I, Park YH, Kim S-B, Borges G, Aksoy S, Gregori JG, Roylance R, Lim E, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Takano T, Egorov A, Wu I, Cathcard J, Chu C, Andre F. Yale Cancer Center, New Haven, CT, USA; Samsung Medical Center, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Clínica de Neoplasias Litoral, Santa Catarina, Brazil; Hacettepe University Medical Faculty, Ankara, Turkey; Instituto Valenciano de Oncologia, Valencia, Spain; University College London Hospital, London, UK; St Vincent’s Hospital Sydney, Sydney, NSW, Australia; Rabin Medical Center-Beilinson Campus, Petah Tikva, Israel; General Hospital of Athens Alexandra, Athens, Greece; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Universitaetsklinikum Düsseldorf AöR, Düsseldorf, Germany; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Daiichi Sankyo, Basking Ridge, NJ, USA; Institut Gustave Roussy, Villejuif, France
|
|
| 9:15 am - 9:30 am CT |
GS2-02: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Pérez-García JM, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paolo, Brazil; National Cheng Kung University Hospital, Tainan, Taiwan; Seoul National University Hospital, Seoul, Republic of Korea; Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France; PSEHOG (Peninsula & South Eastern Haematology and Oncology Group), Frankston, VIC, Australia; Queen Mary Hospital, Hong Kong, China; Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; Nottingham University Hospital, Nottingham, UK; Aichi Cancer Center Hospital, Aichi, Japan; Antwerp University Hospital, Edegem, Belgium; Tom Baker Cancer Centre, Calgary, Alberta, Canada; Istituto Europeo di Oncologia, IRCCS, Milano, Italy; University of Milano, Milano, Italy; International Breast Cancer Center, Quironsalud Group, Barcelona, Spain; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA;International Breast Cancer Center (IBCC), Barcelona, Spain. |
|
| 9:30 am - 9:45 am CT |
GS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
Hurvitz SA, Bardia A (Presenter), Press MF, Wang LS, McAndrew NP, Chan D, Phan V, Villa D, Tetef ML, Chamberlain E, Abdulla N, lomis T, Spring LM, Applebaum S, Dakhil S, DiCarlo B, Kim DD, Kirimis E, Lawler WE, Master AK, McCann K, Hayashi E, Kivork C, Chauv J. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Norris Comprehensive Cancer Center, University of Southern California; PIH Health Downey HOspital, Whittier, CA, USA; UCLA David Geffen School of Medicine; Torrance Memorial Physician Network (TMPN); Cancer Blood and Specialty Clinic; Valley Breast Care and Women's Health Center; Cancer Center of Kansas; Virginia K. Crosson Cancer Center; Associated Surgeons of San Luis Obispo; UCLA JCCC Division of Clinical Trials Development. |
|
| 9:45 am - 11:00 am CT |
HER2 Low: A Separate Entity? Special Session - Hall 3
Chairs: Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center
Pittsburgh, PA
and
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL
HER2 low: A pathologist's perspective
David Rimm, MD, PhD
Yale University
New Haven, CT
Discussants:
Pro
Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy
Con
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Posters:
HER2-01 Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer
Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams m, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center; The University of Texas MD Anderson Cancer Center; MD Anderson Cancer Institute; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
HER2-02 HER2-low status is associated with worse clinical outcomes in hormone receptor-positive, HER2-negative advanced breast cancer patients treated with first-line cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy
Zattarin E, Sposetti C, Leporati R, Mariani L, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Presti D, Provenzano L, Vingiani A, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Berton Giachetti PPM, Carnevale Schianca A, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali DG, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padua; Division of Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy; Farmacia Ospedaliera ASST Cremona, Viale Concordia 1, Cremona; Memorial Sloan Kettering Cancer Center; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; Institut Jules Bordet, Université Libre de Bruxelles (U.L.B); Humanitas University, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS; Department of Surgery, Oncology and Gastroenterology, University of Padua; ASST Spedali Civili; RCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; University of Trieste; Fondazione IRCCS Istituto Nazionale dei Tumori; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
HER2-04 Prevalence of HER2-low among metastatic breast cancer patients and their outcomes compared to HER2 IHC 0
Singareeka Raghavendra A, Liu D, Mouabbi J, Tripathy D. The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
HER2-05 Comprehensive genomic characterization of HER2-low breast cancer
Tarantino P, Gupta HV, Hughes ME, Files JL, Strauss S, Kirkner G, Feeney A-M, Li YY, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky b, MacConaill L, Lindeman N, Johnson B, Meyerson M, Kabraji S, Jeselsohn R, Qiu X, Li R, Long HW, Winer EP, Dillon DA, Curigliano G, Cherniack A, Tolaney SM, Lin NU. Breast Oncology Program, Dana-Farber Cancer Institute; Harvard Medical School; Albert Einstein College of Medicine MSTP (previously: Medical Oncology, Dana-Farber Cancer Institute); Dana Farber Cancer Institute; Medical Oncology, Dana-Farber Cancer Institute; Dana-Farber/Brigham and Women’s Cancer Center; Harvard Medical School; Dasa Oncology; Comprehensive Breast Health Center, Brigham and Women’s Hospital; Breast Oncology Program, Dana-Farber Brigham Cancer Center Division of Cancer Genetics and Prevention; Dana-Farber Cancer Institute; Harvard Medical School; Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of Harvard and MIT; Brigham and Women's Hospital; Harvard Medical School; Medical Oncology, Dana-Farber Cancer Institute; Harvard Medical School; Medical Oncology, Dana-Farber Cancer Institute; Center for Cancer Genomics, Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA; Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Yale Cancer Center; Smilow Cancer Network (previously: Medical Oncology, Dana-Farber Cancer Institute; Breast Oncology Program, Dana-Farber Brigham Cancer Center; Harvard Medical School); Brigham and Women's Hospital, Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy; Medical Oncology, Dana-Farber Cancer Institute; Broad Institute; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School.
HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
Denkert C, Martín M, Untch M, Bonnefoi HR, Knudsen ES, Im S-A, DeMichele A, Witkiewicz A, Van 't Veer L, Kim S-B, Bear HD, McCarthy N, Gelmon K, Marmé F, García-Sáenz JÁ; Turner N, Rojo F, Filipits M, Martin L-A, Fasching PA, Schem C, Kelly CM, Reimer T, TOi M, Rugo HS, Gnant M, Makris A, Liu Y, Weber K, Rachakonda S, Loibl S. Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Germany; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Helios Klinikum Berlin-Buch, Berlin, Germany; Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC); Roswell ; Park Comprehensive Cancer Center; Seoul National University College of Medicine, Seoul, Korea, Republic of (South); Penn Medicine Abramson Cancer Center, Philadelphia PA, USA; Roswell Park Comprehensive Cancer Center; The University of California, San Francisco CA, USA; Asan Medical Center, Seoul, Republic of Korea; Virginia Commonwealth University, Massey Cancer Center; Breast Cancer Trials Australia and New Zealand and University of Queensland Australia; BC Cancer Agency, Vancouver, British Columbia, Canada; Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; Hospital Clínico San Carlos; The Institute of Cancer Research: Royal Cancer Hospital, London, UK; The Autonomous University of Madrid; Center for Cancer Research, Medical University of Vienna, Vienna, Austria; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, UK; Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany; Cancer Trials Ireland; Breast Center, University of Rostock; Graduate School of Medicine , Kyoto University; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Mount Vernon Cancer Centre; Pfizer Inc; German Breast Group, Neu-Isenburg, Germany.
HER2-07 Genomic characterization of primary and metastatic HER2-low breast cancers
Marra A, Safonov A, Drago J, Ferraro E, Selenica P, Gazzo A, Curigliano G, Modi S, Razavi P, Reis-Filho J, Chandarlapaty S. Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center, New York, NY, USA; European Institute of Oncology, IRCCS, University of Milano, Milan, Italy.
HER2-08 Molecular characterization of HER-2 low patients identifies basal-enriched subset with poor clinical outcomes in real-world data
Ahmed T, Stover DG, Hockenberry A, Mackay M, Nimeiri H, Chen J, Ben-Schachar R, Cristofanilli M. Tempus Labs Inc.; The Ohio State University Comprehensive Cancer Center; Weill Cornell Medicine.
HER2-09 Multiomics profiling characterizes distinct HER2-low breast cancer subgroups in the East Asian population
Dai L-J, Ma D, Xiao Y, Jin X, Wu S-Y, Zhao Y-X, Wang H, Yang W-T, Jiang Y-Z, Shao Z-M. Fudan University Shanghai Cancer Center; Department of Oncology, Fudan University Shanghai Cancer Center; Department of Breast Surgery, Fudan University Shanghai Cancer Center.
HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer
Garrido-Castro AC, Ngo LD, Richardson ET, Frangieh A, Mohammed-Abreu A, Hughes ME, Gomez Tejada Zanudo J, Navarro J, Tarantino P, Mittendorf EA, Tolaney SM, King T, Winer EP, Lin NU, Wagle N. Dana-Farber/Brigham and Women’s Cancer Center; Harvard Medical School; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard; Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute; Breast Oncology Program, Dana-Farber Cancer Institute; Harvard Medical School; Dana Farber Cancer Institute; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School; Yale Cancer Center; Smilow Cancer Network (previously: Medical Oncology, Dana-Farber Cancer Institute; Breast Oncology Program, Dana-Farber Brigham Cancer Center; Harvard Medical School); Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; Dana-Farber Cancer Institute.
HER2-11 Epidemiology and prognosis of HER2-low breast cancer (BC) in the National Cancer Data Base (NCDB)
Peiffer D, Howard FM, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D. University of Chicago, Chicago, IL, USA; Alliance for Clinical Trials in Oncology Operations Office; Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago; Department of Public Health Sciences, University of Chicago and Center for Clinical Cancer Genetics & Global Health, Section of Hematology and Oncology, Department of Medicine, University of Chicago.
HER2-12 Genomic and transcriptomic landscape of HER2-low breast cancer
Bansal R, McGrath J, Bustos MA, Rodriguez E, Sammons SL, Accordino MK, Meisel J, Gatti-Mays M, Hsu E, Lathrop KI, Kaklamani V, Korn WM, Oberley M, Walker P, Graff SL. Duke University; Caris Life Sciences; Saint John's Cancer Institute; University of Miami; Duke University; Columbia University Irving Medical Center; Winship Cancer Institute, Atlanta, GA, USA; The Ohio State University Comprehensive Cancer Center; Brown University/Legorreta Cancer Center; UT Health San Antonio; Lifespan Cancer Institute, Providence, RI, USA.
HER2-13 Proficiency assessment of HER2-low breast cancer scoring with the Ventana PATHWAY 4B5 and Dako HercepTest HER2 assays and the impact of pathologist training
Rüschoff J, Penner A, Ellis IO, Hammond MEH, Lebeau A, Osamura RY, Penault-Llorca F, Rojo F, Atkey N, Scheel AH, D' Arrigo C, Schildhaus H-U, Moh A, Desai C, Viale G. Targos Molecular Pathology GmbH, Kassel, Germany; University of Nottingham, Nottingham, UK; Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT, USA; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Diagnostic Pathology, Nippon Koukan Hospital, Kawasaki and Keio University School of Medicine, Tokyo, Japan; Centre de Lutte Contre le Cancer Jean Perrin, Clermont-Ferrand, France; The Autonomous University of Madrid; Diaceutics PLC, Belfast, UK; University of Cologne, Cologne, Germany; Poundbury Cancer Institute for Personalised Medicine, Dorchester, UK; Targos Molecular Pathology GmbH, Kassel, Germany; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; European Institute of Oncology IRCCS, and University of Milan, Milan, Italy.
HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Schwartz CJ, Mukhtar R. University of California, San Francisco; The University of Texas MD Anderson Cancer Center.
HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn JH, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V. European Institute of Oncology IRCCS, and University of Milan, Milan, Italy; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Tokai University School of Medicine, Isehara-shi, Japan; National hospital organization Kyushu Cancer Center; Research Institute for Women's Health, University of Tuebingen, Tuebingen, Germany; Centre de Lutte Contre le Cancer Jean Perrin, Clermont-Ferrand, France; Department of Breast Surgical Oncology, St. Luke's international hospital; Yonsei Cancer Center, Seoul, Republic of Korea; Hospital of Santa Maria, Lisbon, Portugal; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center; The Christie NHS Foundation Trust, Manchester, UK; Medical Faculty of Porto University, Porto, Portugal and Unit of Molecular Pathology of Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal; Medical Statistics Consultancy Ltd, London, UK; AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA; AstraZeneca Computational Pathology, Early Oncology Translational Medicine, Munich, Germany; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; AstraZeneca Pharmaceuticals, Cambridge, UK.
HER2-16 Inter-lesion heterogeneity of HER2-status in metastatic breast cancer: possible implications for treatment with anti-HER2 antibody-drug conjugates
Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Mahdami A, Nguyen H-L, Isnaldi E, Leduc S, Pabba A, Bachir I, Mertens F, Vander Borght S, Smeets A, Nevelsteen I, Punie K, Neven P, Wildiers H, Van Den Bogaert W, Floris G, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium & Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven; Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Belgium; Universitair Ziekenhuis Leuven, Leuven, Belgium; University Hospitals Leuven; Department of Forensic Medicine, University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven; Laboratory for Translation Breast Cancer Research/KU Leuven.
HER2-17 Novel quantitative HER2 assay for determining dynamic HER2 expression in the HER2 IHC 0 “Ultra-Low” setting: Implications for precision therapy in HER2- breast cancer
Corgiat BA, O'Shaughnessy J, LoRusso P, Weinberg K, Davis J, Gawryletz C, Petricoin EF. Theralink Technologies, Inc.; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; Yale Cancer Center; UC Health - Cancer Care and Hematology; George Mason University.
HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
Prat A, Modi S, Tsurutani J, Cameron D, Harbeck N, Garrido C, Karnoub M, Hsu C, Feng W, Yung L, Wang Y, Gambhire D, Ford SK, Vitazka P, Ueno NT. Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Breast Cancer Unit, IOB-Quirón Salud, Barcelona, Spain; Memorial Sloan Kettering Cancer Center; Advanced Cancer Translational Research Institute at Showa University, Tokyo, Japan; Edinburgh University Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score
Spring LM, Barlow WE, Bardia A, SHarma P, Pusztai L, Hortobagyi GN, Kalinsky K. Massachusetts General Hospital Cancer Center, Boston, MA, USA; SWOG Statistics and Data Management Center; University of Kansas Medical Center Westwood, Westwood, KS, USA; Yale University Cancer Center, New Haven, CT, USA; The University of Texas MD Anderson Cancer Center; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
|
|
| 10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
|
| 11:00 am - 12:00 pm CT |
MINI-SYMPOSIUM #1 - Hall 3
C. Kent Osborne HER2 and ER Crosstalk: Signaling the Mechanisms and Clinical Implications Symposium
Moderators: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
and
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Special Guest: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
Oncogene signal transduction and antiestrogen resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
HER2 signaling the ER cistrome
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
Treatment of ER+/HER2+ breast cancer
Stephen Johnston, MBBS
The Royal Marsden Hospital
London, United Kingdom
|
|
| 12:00 pm - 12:30 pm CT |
PLENARY LECTURE #1 - Hall 3
Moderator: Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Lineage-defined Metabolism of Normal Mammary Cells and Origins of Cancer Metabolic Heterogeneity
Rama Khokha, PhD
University Health Network
Toronto, Canada |
|
| 12:30 pm - 1:00 pm CT |
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH, supported by Aflac, Inc. - Hall 3
Moderator: Sibylle Loibl, MD
German Breast Group
Neu-isenburg, Germany
Quantitative Medicine for Breast Cancer Patients
Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC |
|
| 12:30 pm - 1:30 pm CT |
CAREER DEVELOPMENT FORUM - Room 304 |
|
| |
The Career Development Forum provides interactive informational interviews with experts on a variety of topics that are important for the career development of early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2022 SABCS.
Limited to 120 participants; attendance to the in-person Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Badges are required and will be scanned at door for entry. Boxed lunches will be provided.
Participants will have the opportunity to rotate tables every 20 minutes. Some tables topics will have a more clinical focus, while others will have a more laboratory research focus. The subthemes are denoted in parenthesis after the table topic name.
Roundtable Topics
1. Balancing Research and Clinical Practice (Clinical)
2. Becoming a Successful Clinical Trialist (Clinical)
3. Careers in Industry
4. Careers in Basic Science
5. Careers in Translational Research (Clinical)
6. Careers in Translational Research (Laboratory)
7. Career Transitions
8. Negotiating a Job Offer or Promotion
9. How to Get Involved in & Make Collaborative Research Work for You
10. Time Management to Optimize Productivity and Wellness
11. Building a Support Network for Better Work Life Balance
12. Funding Your Own Research
13. Professional Fulfillment and Burnout Mitigation
14. Challenges and Opportunities for Women in Research
15. Promoting Equity and Inclusion in Your Career and Teams |
|
|
1:00 pm - 2:00 pm CT |
CLINICAL CASE DISCUSSION SESSION - Stars at Night Ballroom 1&2 |
|
|
|
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Panelist:
Michael Gnant, MD, FACS, FEBShon
Medical University of Vienna
Vienna, Austria
Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA
Julia Maues
GRASP
Washington, DC
George Sledge, Jr, MD
Stanford University
Stanford, CA
Jonathan Strauss, MD
Northwestern
Chicago, IL
|
|
| 1:00 pm - 2:00 pm CT |
FORUM #1 - Stars at Night Ballroom 3&4
Molecular Aspects of DCIS Progression
Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC
Tumor stroma in DCIS progression
Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA
Clonal evolution of DCIS to invasion
Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands
Defining recurrence risk for DCIS: How do we tailor therapy
Kimberly J. Van Zee, MS, MD, FACS, FSSO
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
|
| 2:00 pm - 3:00 pm CT |
CLINICAL CONTROVERSIES - Hall 3
Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC
To clip or not to clip
Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX
and
Viviana E. Galimberti, MD, MPH
European Institute of Oncology
Milan, Italy
Duration of endocrine therapy
Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN
and
Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL
Post neoadjuvant therapy in TNBC
Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX
and
Susan Domchek, MD
University of Pennsylvania School of Medicine
Philadelphia, PA
|
|
| 2:00 pm - 3:00 pm CT |
MINI-SYMPOSIUM #2 - Stars at Night Ballroom 1&2
Late Recurrence and Tumor Dormancy
Moderator: Alana Welm, PhD
University of Utah
Sal Lake City, UT
NK cells and dormancy
Isaac Chan, MD
UT Southwestern Medical Center
Dallas, TX
Extra cellular matrix and dormancy
Jose Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY
Implications for clinical care
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC
|
|
| 2:00 pm - 3:00 pm CT |
FORUM #2 New Targets and Strategies for Immunotherapy - Stars at Night Ballroom 3&4
Moderator: Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN
Activating a collaborative innate-adaptive immune response to control metastasis
Mikala Egeblad, PhD, MSC
Cold Spring Harbor Laboratory
New York, NY
Neutrophil elastase and anti-tumor effects
Lev Becker, PhD
University of Chicago
Chicago, IL
Immunosuppressive macrophages and PARP inhibitor resistance
Jennifer Guerriero, PhD
Dana-Farber Cancer Institute
Boston, MA
|
|
| 3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #2
EDUCATIONAL SESSION BLOCK #2A - Hemisfair Ballroom 1&2
Digital Health and PROs in Breast Cancer Research and Care
Moderator: Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
What are PROs and evidence for benefit?
Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY
How to incorporate PROs into clinical care
Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Where are we going with digital interventions and PROs
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France
Patient Advocate Perspective
Patty Spears, BS
University of North Carolina
Chapel Hill, NC
EDUCATIONAL SESSION BLOCK #2B - Stars at Night Ballroom 1&2
Antibody Drug Conjugates: Future Directions and Opportunities
Moderator: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT
Bioengineering and mechanism of action of ADC
Puja Sapra, PhD
AstraZeneca
New York, NY
ADCs in breast oncology: Present and future
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Mechanisms of resistance
Leif Ellisen, MD, PhD
Massachusetts General Hospital
Boston, MA
EDUCATIONAL SESSION BLOCK #2C - Stars at Night Ballroom 3&4
Spatial and Single Cell Characterization of Breast Cancer Progression
Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
Single cell profiling
Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia
Multiplex spatial proteomic profiling
David Rimm, MD, PhD
Yale University
New Haven, CT
Imaging mass cytometry of breast cancer
Hamid Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom
Beyond the lab: Clinical implications
Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA
EDUCATIONAL SESSION BLOCK #2D - Hemisfair Ballroom 3
Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know
Moderators: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Susan Dent, MD
Duke University
Durham, NC
Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents
Susan Dent, MD
Duke University
Durham, NC
Radiation therapy and cardiovascular disease in breast cancer
Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Cardiovascular toxicity and breast cancer: Detection and prevention strategies
Dinesh Thavendiranathan, MD, MSc
Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto
Toronto, Canada
Perspective 1: Cardiac problems secondary to chemotherapy
Kiran Dhillon, PhD
UW Medicine
Seattle, WA
Perspective 2: Cardiac problems secondary to chemotherapy
Alexea Gaffney-Adams, Dr. Med
Alexea Gaffney-Adams
New York, NY
|
|
| 5:00 pm - 6:15 pm CT |
POSTER SESSION #3 and ONGOING TRIALS POSTER SESSION 2 - Hall 1 |
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #7 - Stars at Night Ballroom 3&4
Brain Metastases
Chair: Andrew Brenner, MD, PhD
UT Health San Antonio
San Antonio, TX
Treatment
Barbara O'Brien
UT MD Anderson Cancer Center
Houston, TX
Prognosis
Carey K. Anders, MD
Duke University
Durham, NC
Laura Crandon, MBA, Advocate
Touch4Life
Clarksville, MD
|
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #8 - Stars at Night Ballroom 1&2
Symptom Management and Associate Toxicities
Chair: Dawn Hershman, MD
Columbia University
New York, NY
Symptom management
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France
Psychosocial needs
Michelle Melisko
University California San Francisco
San Francisco, CA
Patient Advocate
Barbara Segarra Vazquez, DSc
University of Puerto Rico
San Juan, Puerto Rico
|
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #9 - Hemisfair Ballroom 1&2
Immune Landscape and Microenvironments
Chair: W. Fraser Symmans, MB ChB
UT MD Anderson Cancer Center
Houston, TX
Michail Ignatiadis, MD, PhD
Institut Jules Bordet
Brussels, Belgium
Daniel G. Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH
|
|
|
OPEN SATELLITE EVENTS - Marriott Rivercenter
|
|
| |
|
|
| 7:00 pm CT |
Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy presented by Clinical Care Options, LLC
For more information and to register visit our website https://www.clinicaloptions.com/BreastEBCSanAntonio2022
|
|
| 7:15 pm - 9:15 pm CT |
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research to Practice
San Antonio Marriott Rivercenter, Grand Ballroom G-M, Third Floor
For more information and to register visit our website http://www.researchtopractice.com/Meetings/SA2022
|
|
|